JMJD7-IN-1 is a potent JMJD7 inhibitor with IC50 value of 6.62μM.

CY3 is a reactive dye for the labeling of amino-groups in biomolecules.

GSK-J2 is a pyridine regio-isomer of GSK-J1 which poorly inhibits JMJD3 (IC50 > 100 μM), making it an appropriate negative control for in vitro studies involving GSK-J1 and is a selective inhibitor for human H3K27me3 demethylases.

GSK J4 is a cell permeable prodrug rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor and attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 μM for the inhibition of TNFα release).

GSK-J4 HCl is selective inhibitor of jumonji H3K27 demethylase. It can attenuate lipopolysaccharide (LPS)-induced proinflammatory cytokine production.

CC-90011 is a potent and orally active LSD1 inhibitor. It is in phase I clinical study of CC-90011 in patients (pts) with advanced unresectable solid tumors and R/R NHL.

ML324 is an inhibitor of JMJD2 demethylase with IC50 of 920 nM with antiviral activity.